bluuebunny/crossref_metadata_2025_split huggingface dataset:
Mechanical thrombectomy in orally anticoagulated patients with acute ischemic stroke
Authors: Zapata-Wainberg Gustavo , Ximénez-Carrillo Álvaro , Trillo Santiago , Fuentes Blanca , Cruz-Culebras Antonio , Aguirre Clara , Alonso de Leciñana María , Vera Rocío , Bárcena Eduardo , Fernández-Prieto Andrés , Méndez-Cendón José Carlos , Caniego Jose Luis , Díez-Tejedor Exuperio , Masjuan Jaime , Vivancos José 
Published: December 2017

Background and purposeTo investigate the efficacy and safety of mechanical thrombectomy in patients with acute ischemic stroke according to the oral anticoagulation medication taken at the time of stroke onset.Materials and methodsA retrospective multicenter study of prospectively collected data based on data from the registry the Madrid Stroke Network was performed. We included consecutive patients with acute ischemic stroke treated with mechanical thrombectomy and compared the frequency of intracranial hemorrhage and the modified Rankin Scale (mRS) score at 3 months according to anticoagulation status.ResultsThe study population comprised 502 patients, of whom 389 (77.5%) were not anticoagulated, 104 (20.7%) were taking vitamin K antagonists, and 9 (1.8%) were taking direct oral anticoagulants. Intravenous thrombolysis had been performed in 59.8% and 15.0% of non-anticoagulated and anticoagulated patients, respectively. Rates of intracranial hemorrhage after treatment were similar between non-anticoagulated and anticoagulated patients, as were rates of recanalization. After 3 months of follow-up, the mRS score was ≤2 in 56.3% and 55.7% of non-anticoagulated and anticoagulated patients, respectively (P=NS). Mortality rates were similar in the two groups (13.1%and12.4%, respectively). Among anticoagulated patients, no differences were found for intracranial bleeding, mRS score, or mortality rates between patients taking vitamin K antagonists and those taking direct oral anticoagulants.ConclusionsMechanical thrombectomy is feasible in anticoagulated patients with acute ischemic stroke. The outcomes and safety profile are similar to those of patients with no prior anticoagulation therapy.
Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors
Authors: Gho Johannes M I H , Postema Pieter G , Conijn Maartje , Bruinsma Nienke , de Jong Jonas S S G , Bezzina Connie R , Wilde Arthur A M , Asselbergs Folkert W 
Published: December 2017

ObjectiveThe aim of the current study was to determine the contemporary incidence, risk factors and prognosis of heart failure (HF) after ST-elevation myocardial infarction (STEMI).MethodsWe used the Arrhythmia Genetics in the Netherlands observational cohort study to identify patients with a first STEMI from 2001 onwards (n=1459). HF during follow-up was defined as hospitalisation for HF or an outpatient clinic visit for HF. Cox regression was performed to estimate the relationship between baseline covariates and the onset of HF.ResultsFollow-up was completed for 1360 (93.2%) patients with an overall median follow-up time of 6.7 years, 1232 (90.6%) of these patients had undergone primary percutaneous coronary intervention (PCI). A total of 85 patients (6.3%) developed HF during follow-up. HF cases were significantly older at their index MI (59.9 vs 57.2 years, P<0.001) and more commonly had a history of atrial fibrillation (6.1% vs 1.4%, P=0.001) than controls without HF. The crude incidence rate of HF after STEMI was 9.7 (95% CI 7.7 to 11.8) per 1000 person-years. In multivariable analysis, peak creatine kinase MB (CK-MB) levels (HR 1.11 per 100 U/L (95% CI 1.11 to 1.22)) and a left anterior descending artery (LAD) culprit lesion (HR 2.88 (95% CI 1.53 to 5.40)) were risk factors associated with HF.ConclusionsWe found a relatively low long-term contemporary incidence of HF after a first STEMI in the current PCI era in comparison with other reports. Higher CK-MB levels and a LAD culprit lesion at index STEMI were important risk factors for the development of HF after STEMI.Trial registration numberNCT03007199; Results.
Chronic but not inflammatory changes at the Achilles’ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses – Results from a prospective clinical trial
Authors: Baraliakos Xenofon , Kiltz Uta , Appel Heiner , Dybowski Friedrich , Igelmann Manfred , Kalthoff Ludwig , Klink Claudia , Krause Dietmar , Saracbasi Ertan , Schmitz-Bortz Elmar , Rahmeh Feras , Braun Juergen 
Published: December 2017

BackgroundImaging has an essential role in the new spondyloarthritis (SpA) classification criteria for axial but not for peripheral manifestations. We evaluated the impact of imaging findings for identification and treatment decisions in patients with peripheral spondyloarthritis (pSpA) and controls (non-SpA).MethodsPatients with pSpA (Assessment of SpA international Society criteria, n=30) and non-SpA (n=30), aged <45 years, with painful heels or knees, were recruited. Conventional radiography, grey-scale ultrasound including power Doppler (US/PDUS) and MRI of symptomatic areas were performed to assess inflammatory and structural changes. Mann-Whitney U test was used for group comparisons.ResultsIn total, 105 painful entheses (71 heels, 34 knees) in 60 patients were examined. Differences between diagnoses were found for symptom duration (pSpA: 17.2±27.5 vs non-SpA: 4.4±4.3 months), human leucocyte antigen B27 prevalence (67% vs 13%) and gender distribution (53.3% vs 20% male, respectively), all P<0.05. Logistic regression analysis for baseline differences showed that chronic changes (erosions and calcification) in the heel were more frequent in pSpA versus non-SpA by US/PDUS (62.5% vs 28.6% patients and 59.5% vs 26.5% entheses, P<0.05). Inflammatory changes in heel or knee by US/PDUS and MRI could not differentiate between non-SpA and pSpA.ConclusionsDifferentiation between pSpA and non-SpA was only possible based on structural but not inflammatory changes in the heels and knees of symptomatic patients. US/PDUS was superior to MRI for this purpose. These findings imply that pSpA is associated with erosive changes at enthesitic sites, while inflammation and susceptibility are of minor influence for the development of erosions and calcification to pSpA.
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
Authors: Coates Laura C , Kishimoto Mitsumasa , Gottlieb Alice , Shuler Catherine L , Lin Chen-Yen , Lee Chin Hyok , Mease Philip J 
Published: December 2017

ObjectiveTo evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239).MethodsPatients were stratified by cDMARD use (concomitant cDMARDs use (including methotrexate) or none (past or naïve use)) and randomly assigned to treatment groups (ixekizumab 80 mg every 4 weeks (IXEQ4W) or every 2 weeks (IXEQ2W) or placebo). Efficacy was evaluated versus placebo at week 24 by the American College of Rheumatology criteria (ACR20/50/70), modified total Sharp score and Health Assessment Questionnaire-Disability Index (HAQ-DI). Safety was assessed according to cDMARD status.ResultsRegardless of concomitant cDMARD usage, ACR20, ACR50 and ACR70 response rates were significantly higher versus placebo with IXEQ4W and IXEQ2W. The proportion of patients achieving HAQ-DI minimal clinically important difference was significantly higher versus placebo with IXEQ4W with concomitant cDMARD use and IXEQ2W, regardless of concomitant cDMARD use. Treatment-emergent adverse events (AE) were more frequent versus placebo for either ixekizumab-dosing regimen, regardless of concomitant cDMARD use. Serious AEs were not higher versus placebo, regardless of concomitant cDMARD use.ConclusionIxekizumab treatment improved measures of disease activity and physical function in patients with active PsA relative to placebo, when used with or without concomitant cDMARD therapy.
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
Authors: Prieto-González Sergio , Terrades-García Nekane , Corbera-Bellalta Marc , Planas-Rigol Ester , Miyabe Chie , Alba Marco A , Ponce Ariel , Tavera-Bahillo Itziar , Murgia Giuseppe , Espígol-Frigolé Georgina , Marco-Hernández Javier , Hernández-Rodríguez José , García-Martínez Ana , Unizony Sebastian H , Cid Maria C 
Published: December 2017

BackgroundOsteopontin (OPN) is a glycoprotein involved in Th1 and Th17 differentiation, tissue inflammation and remodelling. We explored the role of serum OPN (sOPN) as a biomarker in patients with giant cell arteritis (GCA).MethodssOPN was measured by immunoassay in 76 treatment-naïve patients with GCA and 25 age-matched and sex-matched controls. In 36 patients, a second measurement was performed after 1 year of glucocorticoid treatment. Baseline clinical and laboratory findings, as well as relapses and glucocorticoid requirements during follow-up, were prospectively recorded. sOPN and C reactive protein (CRP) were measured in 32 additional patients in remission treated with glucocorticoids or tocilizumab (interleukin 6 (IL-6) receptor antagonist). In cultured temporal arteries exposed and unexposed to tocilizumab, OPN mRNA expression and protein production were measured by reverse transcription polymerase chain reaction (RT-PCR) and immunoassay, respectively.ResultssOPN concentration (ng/mL; mean±SD) was significantly elevated in patients with active disease (116.75±65.61) compared with controls (41.10±22.65; p<0.001). A significant decline in sOPN was observed in paired samples as patients entered disease remission (active disease 102.45±57.72, remission 46.47±23.49; p<0.001). sOPN correlated with serum IL-6 (r=0.55; p<0.001). Baseline sOPN concentrations were significantly higher in relapsing versus non-relapsing patients (relapsers 129.08±74.24, non-relapsers 90.63±41.02; p=0.03). OPN mRNA expression and protein production in cultured arteries were not significantly modified by tocilizumab. In tocilizumab-treated patients, CRP became undetectable, whereas sOPN was similar in patients in tocilizumab-maintained (51.91±36.25) or glucocorticoid-maintained remission (50.65±23.59; p=0.49).ConclusionssOPN is a marker of disease activity and a predictor of relapse in GCA. Since OPN is not exclusively IL-6-dependent, sOPN might be a suitable disease activity biomarker in tocilizumab-treated patients.
Emergency department management of patients with rib fracture based on a clinical practice guideline
Authors: Hamilton Chase , Barnett Lauren , Trop Allison , Leininger Brian , Olson Adam , Brooks Aaron , Clark Daniel , Schroeppel Thomas 
Published: December 2017

BackgroundClinical practice guidelines (CPGs) have the ability to increase efficiency and standardize care. A CPG based on forced vital capacity (FVC) for rib fractures was developed as a tool for triage of these patients. The objectives of this study were to assess the efficacy and compliance of physicians with this rib fracture CPG.MethodsPatients >18 that were discharged from an urban level 2 trauma center emergency department (ED) between the dates of January 1, 2014, to December 31, 2016, were eligible for the study. Demographics, mechanism, outcomes and FVC were abstracted by review of the electronic medical record. Compliance with the CPG was examined, and comparisons were made between patients successfully discharged and patients who returned.Results455 patients met were identified during the study period. 233 were eligible after exclusions. 64% of the cohort was male with median age of 53 years. Falls were the most common mechanism (59.6%). The median number of rib fractures was 2 and median FVC 2500 mL. 28 (12.0%) of the 233 returned to the ED after discharge. The groups were well matched with no significant differences. The most common reason for return was pain (95%). Adjusted analysis showed that increasing age (adjusted OR (AOR) 0.968) and FVC (AOR 0.999) were independent predictors. Adherence with the CPG was good for hemothorax/pneumothorax and bilateral fractures (96%), but lagged with the number of fractures (74%).ConclusionsThis study confirms that the rib fracture CPG is safe and an FVC of 1500 mL is a safe criterion for discharging patients with rib fractures. Interestingly, it appears that older age is protective. More work needs to be done on effective pain control to decrease return to ED visits using this CPG.Level of evidenceIV.Type of studyTherapeutic.
Thymic haemorrhage due to ingestion of human anticoagulant medication in a puppy
Authors: Vangrinsven Emilie , Girod Maud , Etienne Anne‐Laure , Gommeren Kris 
Published: December 2017

A four‐month‐old male Shih‐Tzu was presented with lethargy, mild dyspnoea and acute thoracic pain. Thoracic radiography revealed the presence of a mediastinal mass at the level of the thymus and ultrasound confirmed a thymic haemorrhage. Coagulation times were beyond the detection limit of the machine. After preprandial and postprandial bile acids excluded hepatic insufficiency, an anticoagulant intoxication was strongly suspected. Disappearance of multiple doses of phenprocoumon in the house and rapid response to vitamin K administration as a treatment and blood transfusion confirmed authors' suspicion. The dog had clinically made a full recovery and was discharged after 36 hours. The following unique information has been provided: anticoagulant intoxication is commonly seen but the clinical presentation can be highly variable depending on the affected area. This report describes a rare thymic haemorrhage secondary to ingestion of human anticoagulant medication in a dog.
(Na + K + 2Cl) cotransport in cultured embryonic chick heart cells
Authors: Liu Shi , Jacob Ron , Piwnica-Worms David , Lieberman Melvyn 
Published: December 2017

Pages C721–C730: Shi Liu, Ron Jacob, David Piwnica-Worms, and Melvyn Lieberman.“(Na + K + 2Cl) cotransport in cultured embryonic chick heart cells.” Page C721: first and second sentences, second paragraph, second column, should read “In this study, coupled ion movements are investigated using Na-, K-, and Cl-selective microelectrodes, in contrast to previous work (30), in which we determined the contents of Na, K, and Cl by atomic absorption spectrophotometry (Nai and Ki) or coulometric titration (Cli). We find that Cl-HCO3 exchange does not appear to contribute to the maintenance of a high agrCli in the resting steady state.7#x201D; C722: Eq. 1 should read (See PDF)
Effects of CGRP, forskolin, PMA, and ionomycin on pHi dependence of Na-H exchange in UMR-106 cells
Authors: Gupta Anandarup , Schwiening Christof J. , Boron Walter F. 
Published: December 2017

1 Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut 06510 We examined the effects of calcitonin gene-related peptide (CGRP), forskolin, phorbol 12-myristate 13-acetate (PMA), and ionomytin on the intracellular pH (pHi) dependence of Na-H exchange in UMR-106 cells. In the nominal absence of CO2-HCO3-, each agent increased pHi, measured with 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF). From the rate of pHi recovery (dpHi/dt) from an acid load, and intracellular buffering power, we computed the pHi dependence of the total acid-extruding flux (JTotal). All four agents increased JTotal. From dpHi/dt data obtained in the presence of ethylisopropyl amiloride (EIPA, a blocker of Na-H exchange), we determined the EIPA-resistant component of JTotal (JEIPA/R). We estimated the Na-H exchange flux (JNa-H as the difference JTotal - JEIPA/R. CGRP, forskolin, and PMA produced similar increases in the slope of the JNa-H vs. pHi-relationship. The net effect of these agents, as well as ionomycin, was to increase JNa-H over a broad pHi range. Ionomycin alkaline shifted the JEIPA/R vs. pHi relationship; the other agents had no effect. Our results indicate that CGRP increased JTotal by stimulating Na-H exchange, with little effect on EIPA-resistant processes. A signaling pathway involving only adenosine 3',5'-cyclic monophosphate, only protein kinase C, or only Ca2+ cannot account for the effects of CGRP on both pHi and pHi dependence of JNa-H. Thus, CGRP probably affects UMR-106 pHi physiology via more than one pathway. acid-base balance; ion transport; ethylisopropyl amiloride; amiloride analogs; osteoblasts; fluorescence; 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein; calcium; adenosine 3',5'-cyclic monophosphate; protein kinase C Submitted on February 19, 1993 Accepted on October 8, 1993
MRF4, Myf-5, and myogenin mRNAs in the adaptive responses of mature rat muscle
Authors: Jacobs-El J. , Zhou M. -Y. , Russell B. 
Published: December 2017

Pages C1045-C1052: J. Jacobs-El, M.-Y. Zhou, and B. Russell. “ MRF4, Myf-5, and myogenin mRNAs in the adaptive responses of mature rat muscle.” Pages C1049 and C1051, Figs. 4 and 6 were inadvertently switched, although the legends as placed are correct. The correct Figs. 4 and 6 with their legends are as follows. (See PDF)
MRF4, Myf-5, and myogenin mRNAs in the adaptive responses of mature rat muscle
Authors: Jacobs-El J. , Zhou M. -Y. , Russell B. 
Published: December 2017

Pages C1045,C1052: J. Jacobs-El, M.-Y. Zhou, and B. Russell. “MRF4, Myf-5, and myogenin mRNAs in the adaptive responses of mature rat muscle.” Pages C1049 and C1051, Figs. 4 and 6 were inadvertently switched, although the legends as placed are correct. The correct Figs. 4 and 6 with their legends are as follows. (See PDF)
Letters to the Editor
Authors: Adorante Joseph S. , Edelman Jeffrey L. 
Published: December 2017

The following is the abstract of the article discussed in the subsequent letter: Mitchell, Claire H., Jin Jun Zhang, Liwei Wang, and Tim J. C. Jacob. Volume-sensitive chloride current in pigmented ciliary epithelial cells: role of phospholipases. Am. J. Physiol. 272 ( Cell Physiol. 41): C212–C222, 1997.—The whole cell recording technique was used to examine an outwardly rectifying chloride current activated by hypotonic shock in bovine pigmented ciliary epithelial (PCE) cells. Removal of internal and external Ca2+ did not affect the activation of these currents, but they were abolished by the phospholipase C inhibitor neomycin. The current was blocked by 5-nitro-2-(3-phenylpropylamino)benzoic acid, 4-acetamido-4′-isothiocyanostilbene-2,2′-disulfonic acid, and 4,4′-diisothiocyanostilbene-2,2′-disulfonic acid (DIDS) in a voltage-dependent manner, but tamoxifen, dideoxyforskolin, and quinidine did not affect it. This blocking profile differs from that of the volume-sensitive chloride channel in neighboring nonpigmented ciliary epithelial cells (Wu, J., J. J. Zhang, H. Koppel, and T. J. C. Jacob. J. Physiol. Lond. 491: 743–755, 1996), and this difference implies that the volume responses of the two cell types are mediated by different chloride channels (Jacob, T. J. C., and J. J. Zhang. J. Physiol. Lond. In press). Intracellular administration of guanosine 5′- O-(3-thiotriphosphate) (GTPγS) to PCE cells induced a transient, time-independent, outwardly rectifying chloride current that closely resembled the current activated by hypotonic shock. DIDS produced a voltage-dependent block of the GTPγS-activated current similar to the block of the hypotonically activated current. Intracellular neomycin completely prevented activation of this current as did incubation of the cells in calphostin C, an inhibitor of protein kinase C (PKC). Removal of Ca2+ did not affect activation of the current by GTPγS but extended the duration of the response. Inhibition of phospholipase A2 (PLA2) with p-bromophenacyl bromide prevented the activation of the hypotonically induced current and also inhibited the current once activated by hypotonic solution. The findings imply that the hypotonic response in PCE cells is mediated by both phospholipase C (PLC) and PLA2. Both phospholipases generate arachidonic acid, and, in addition, the PLC pathway regulates the PLA2 pathway via a PKC-dependent phosphorylation of PLA2.
Vascular reactivity of contralateral kidney in awake Goldblatt hypertensive dog
Authors: Zimmerman Ben G. 
Published: December 2017

Pages H1043–H1049: Ben G. Zimmerman. “Vascular reactivity of contralateral kidney in awake Goldblatt hypertensive dog.” Page H1044: methods, fourth sentence should read “In a second operative procedure, an electromagnetic blood flow probe (4–6 mm Zepeda Instruments, Seattle, WA) was installed around and a small catheter (PE-10 tubing) inserted into the left renal artery, as previously described (34).” Page H1045: Table 2 should appear as follows: (See PDF)
A field and circuit thermodynamics for integrative physiology. I. Introduction to the general notions
Authors: Iberall A. S. 
Published: December 2017

Page R171: A. S. Iberall. “A field and circuit thermodynamics for integrative physiology. I. Introduction to the general notions.” Page R176: delete Vs,s from Eqs. 8 and 9, which should now read (See PDF)
Strength of human metatarsal bones under repetitive loading
Authors: Lease Glenn O'D. , Evans F. Gaynor 
Published: December 2017

The fatigue life of 51 intact human metatarsals was tested in a Sonntag Flexure Fatigue machine equipped with an automatic counter and shutoff. Bones from eight adult males and three females were used. Nine of the individuals were white and two were Negro. No bones showed any gross pathology. Ten bones were tested wet, forty-one dry. The repetitions to failure with a 15-lb. load, the maximum applied, varied from 1,000 to 10,297,000 for the dry specimens and from 150,000 to 13,908,000 for the wet ones. The greatest variation between the minimum and maximum number of repetitions to failure was 10,287,000 and 10,966,000 repetitions for the dry and wet specimens, respectively. Metatarsals II and III had the longest fatigue life when wet while metatarsals IV and V had the greatest fatigue life when dry. No consistent relations were found between the fatigue life of the bones and their size or the age of the individual from whom they were obtained. The fractures produced were of the comminuted and oblique types found clinically. As far as is known the fatigue life of intact bones has not been previously studied. Submitted on June 30, 1958
Alterations in lung compliance and functional residual capacity with posture
Authors: Lim Thomas P. K. , Luft Ulrich C. 
Published: December 2017

Lung compliance and functional residual capacity were determined in the erect standing and the supine lying positions on six normal adults. Both lung compliance and functional residual capacity were proportionally reduced on resuming the supine from the standing position so that the ‘specific compliance’ remained the same at the two body positions. The correlation between lung compliance and FRC found in this study agrees well with that reported by others and the importance of considering the size of the system in assessing elastic properties of the lung is briefly discussed. Submitted on October 17, 1958